A bifunctional MSC engineered with TRAIL and expressing the anti-GD2 CAR can enhance its antitumor abilities with site-specific targeting GD2 highly expressed in glioblastoma (GBM) [132]. Here, TNFSF10 is linked to glioblastoma.